Podcasts about biotech

In 1987, Mary P. Lovato, a member of Kewa Pueblo in New Mexico, was diagnosed with acute leukemia. To receive a bone marrow transplant, she had to travel more than 800 miles from home because specialized cancer care was unavailable through the Indian Health Service. When she returned, she discovered another obstacle: many in her community feared cancer so deeply that they avoided speaking about it altogether.This episode examines how cancer survivorship exposed profound inequities in the American healthcare system. Long before health equity became a national priority, advocates from underserved communities were confronting disparities rooted in geography, poverty, racism, language, underfunded healthcare systems, and historical mistrust of medical institutions. Their work demonstrated that scientific advances alone cannot improve survival if patients cannot reach, afford, or trust the care available to them.The story follows pioneers including Mary P. Lovato, who built the first national Native-led cancer support and education program for Indigenous communities, and Maimah Karmo, founder of the Tigerlily Foundation, whose breast cancer diagnosis inspired a movement to improve early detection, clinical trial participation, and representation for Black women. Their advocacy challenged longstanding barriers to culturally competent care while highlighting persistent inequities in access to screening, fertility preservation, navigation, and innovative treatments.The episode also explores why diversity in clinical research matters. For decades, many cancer clinical trials disproportionately enrolled White patients, limiting both access to promising therapies and the scientific understanding of how treatments perform across different populations. Researchers, patient advocates, and community leaders responded by redesigning outreach, improving patient navigation, reducing logistical barriers, and insisting that affected communities help shape the research itself.Cancer survivorship cannot be measured solely by scientific breakthroughs. It also depends on whether every patient has a meaningful opportunity to benefit from them. The pursuit of health equity remains one of the defining challenges and enduring responsibilities of modern oncology.RELATED LINKSNational Cancer Institute | Cancer Health Disparities⁠Indian Health Service⁠Tigerlily Foundation⁠National Cancer Institute | Cancer Clinical Trials⁠American Indian Cancer Foundation⁠Abramson Cancer Center | University of Pennsylvania⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Olivier Litzka, Partner at Andera Partners, talks about what it really takes for biotech companies to attract capital, stay focused, and survive the moments when biology and execution punch back. Olivia also discusses a collaborative effort in Europe to create a stronger public market and investor base, and what the emergence of AI and Chinese biotech means for building tomorrow's biotech companies. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Deux tiers des maladies connues n'ont aucun traitement efficace.Pourtant, les géants de la pharma ont arrêté de chercher.D'ici 2033, l'industrie pharmaceutique mondiale perdra 400 milliards de dollars de chiffre d'affaires par an, à mesure que ses brevets tombent dans le domaine public.Aujourd'hui, plus de 70% des médicaments innovants vendus viennent de petites entreprises, des biotechs, qu'elle rachète pour combler ce trou.C'est ici que Rafaèle Tordjman a décidé d'agir.Double docteure en médecine et en sciences, elle a soigné des cancers du sang à Saint-Louis et à Necker, avant de passer une thèse de sciences et un post-doctorat à l'Inserm.Après ses études, Rafaèle quitte l'hôpital car elle comprend que pour mieux servir les patients, il faut accélérer l'innovation.Mais cette innovation ne naît ni dans les hôpitaux, ni chez les géants de l'industrie.Elle naît dans les petites biotechs.Alors en 2018, elle fonde Jeito Capital pour accompagner ces structures.Aujourd'hui, Jeito gère 1,6 milliard d'euros et est devenu le plus gros fonds biopharma indépendant d'Europe.Pendant deux heures trente, Rafaèle décrypte une industrie qu'on ne nous explique jamais :Pourquoi les géants de la pharma ont arrêté de chercher et rachètent les molécules des petites biotechs à coups de milliardsCe que la Chine a déjà craqué sur le médicament, et la carte qui reste à jouer pour l'EuropePourquoi certains médicaments n'existeront jamais, même quand la maladie tueLes vrais chiffres derrière chaque médicament sur le marchéLes maladies du siècle et comment les prévenirUne plongée dans le modèle économique du médicament, racontée par une femme qui l'observe des deux côtés : au chevet du patient, et au capital des entreprises qui le soignent.Vous pouvez contacter Rafaèle sur Linkedin.TIMELINE:00:00:00 - Deux tiers des maladies sont sans traitement 00:13:17 - Le problème avec la chimiothérapie 00:18:41 - Financer les médicaments que les géants rachètent des milliards 00:27:00 - Le calendrier des brevets décide tout 00:34:31 - Concevoir un fonds comme une entreprise 00:42:29 - Les chiffres derrière chaque médicament sur le marché 00:55:31 - Transforme sa thèse de doctorat en entreprise 01:01:57 - 70 % de l'innovation ne vient pas des big pharma 01:11:19 - RGPD, le boulet de l'innovation médicale 01:25:06 - La santé, un secteur sans cycle et sans bulle 01:31:58 - Pourquoi certains médicaments n'existeront jamais 01:44:31 - Les maladies du siècle 01:54:45 - Les chiffres derrière un fonds biopharma d'un milliard 02:03:18 - L'œil humain reste indispensable 02:16:00 - 80 % des décisions de santé dans les familles sont prises par des femmes 02:25:27 - Le polar pour comprendre l'industrie du médicamentLes anciens épisodes de GDIY mentionnés : #543 - Yann Le Cun - AMI Labs - Rendre l'IA plus humaine#507 - Laurent Alexandre - Vers la fin des études supérieures ?#426 - Thomas Clozel - Owkin - Comment casser Big Pharma grâce à l'IA#397 - Yann Le Cun - Chief AI Scientist chez Meta - L'Intelligence Artificielle Générale ne viendra pas de Chat GPT#372 - Alexandre Jenny - Pixfield - L'incroyable histoire du geek de Chambéry derrière la GoPro 360#327 - Laurent Alexandre - Auteur - ChatGPT & IA : "Dans 6 mois, il sera trop tard pour s'y intéresser"#165 - Laurent Alexandre - Doctissimo - La nécessité d'affirmer ses idéesNous avons parlé de :JeitoDr. HouseKeytrudaOVNI CapitalMécanismes de l'effet placebo et du conditionnementQu'est ce qu'un essai en double aveugle ?Institut PasteurDASSAULT : le Fleuron de la défense FrançaiseUS Food and Drug AdmninistrationComment la Chine est devenue imbattable ?Les recommandations de lecture :For Blood and Money: Billionaires, Biotech, and the Quest for a Blockbuster Drug, by Nathan Vardi

In 2000, Katie Couric underwent a live colonoscopy on national television following the death of her husband, Jay Monahan, from colorectal cancer at age 42. The broadcast demystified a procedure many Americans feared, led to an estimated 20% increase in colonoscopy screenings, and became one of the clearest examples of how public storytelling can change healthcare behavior.This episode examines how celebrities, journalists, filmmakers, and entertainers helped reshape the public conversation about cancer during a period when survivorship was becoming increasingly visible. As breakthroughs in targeted therapies, immunotherapy, and early detection allowed more people to live beyond cancer, public figures used their platforms to encourage screening, reduce stigma, and accelerate research. Their influence extended far beyond awareness campaigns, helping transform cancer from a private diagnosis into a national public health conversation.Central to this story is Laura Ziskin, the Hollywood producer behind Pretty Woman and the Spider-Man films, whose metastatic breast cancer diagnosis inspired the creation of Stand Up To Cancer. Working alongside Couric and leaders from entertainment, journalism, and biomedical research, Ziskin championed a new funding model that required multidisciplinary scientific collaboration, helping accelerate discoveries that contributed to multiple FDA-approved cancer therapies. The episode also highlights the advocacy of actor Patrick Dempsey, whose family's experience with ovarian cancer led to the creation of the Dempsey Center, expanding support for patients and caregivers beyond medical treatment.The story also asks what celebrity advocacy often leaves unsaid. Financial toxicity, caregiver burden, chronic pain, mental health, and the long-term effects of treatment rarely receive the same attention as dramatic diagnoses or breakthrough cures. As cancer survivorship continues to evolve, the greatest challenge may not be convincing people to care about cancer, but helping them understand what it truly means to live with and beyond it.RELATED LINKSStand Up To Cancer⁠Katie Couric Media⁠Dempsey Center⁠American Association for Cancer Research⁠National Cancer Institute⁠Dana-Farber Cancer Institute | Adult Survivorship Program⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In 2006, a landmark report titled Closing the Gap: Research and Care Imperatives for Adolescents and Young Adults with Cancer confirmed what young survivors had been saying for years. While survival rates for children and older adults had steadily improved, adolescents and young adults had experienced decades of stalled progress. They had become cancer's lost generation.This episode explores how young adult survivors transformed their shared isolation into one of the most influential grassroots movements in cancer advocacy. Diagnosed during the years typically devoted to education, careers, relationships, and starting families, patients between the ages of 15 and 39 confronted challenges that extended far beyond treatment. Fertility preservation, sexual health, employment, financial toxicity, insurance, and long-term quality of life were rarely discussed in oncology clinics, leaving many to navigate survivorship alone.The episode follows advocates including Tamika Felder, Lindsay Avner, Heidi Adams, Doug Ulman, and Dr. Archie Bleyer, whose research and advocacy fundamentally changed how medicine understands adolescent and young adult cancer. Through organizations including Planet Cancer, Fertile Hope, the Lance Armstrong Foundation, and later Stupid Cancer, survivors built online communities, educational resources, conferences, and national partnerships that challenged long-standing assumptions about cancer care. Their work helped establish fertility preservation as a standard discussion before treatment, expanded research dedicated to adolescent and young adult oncology, and elevated quality of life as a critical clinical outcome alongside survival.The movement also demonstrated the power of lived experience to reshape medicine. Survivors became researchers, educators, nonprofit founders, and policy advocates, insisting that cancer care account not only for years of life saved, but for the lives patients hoped to build afterward.What began as a search for peers evolved into a national movement that permanently transformed adolescent and young adult oncology. Today, dedicated research programs, clinical fellowships, survivorship resources, and patient advocacy organizations continue to build on the foundation these young cancer mavericks created.RELATED LINKSNational Cancer Institute | Adolescent and Young Adult (AYA) Cancer Program⁠Closing the Gap: Research and Care Imperatives for Adolescents and Young Adults with Cancer⁠American Society of Clinical Oncology | Fertility Preservation Guidelines⁠Stupid Cancer⁠Livestrong Foundation⁠Journal of Adolescent and Young Adult Oncology⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

August 25, 2026: Your daily rundown of health and wellness news, in under 5 minutes. Today's top stories: Oura faces a proposed class action over sleep-tracking accuracy claims just months after filing for an IPO at an $11B valuation Lady Gaga and Michael Polansky launch Outer Biosciences, using living human skin and AI to discover new skincare ingredients with four leads nearing commercialization Research and Markets projects global men's health and wellness will reach $2.88T by 2030, expanding well beyond supplements and gym memberships Today's episode is brought to you by AIIR — a modern communications and experiential agency for health, wellness, fitness, and performance brands. From earned media to events and creator-led campaigns, AIIR helps companies sharpen their story, earn attention, and build trust that compounds. Visit https://aiir.agency to learn more. More from Fitt: Fitt Insider breaks down the convergence of fitness, wellness, and healthcare — and what it means for business, culture, and capital. Subscribe to our newsletter → insider.fitt.co/subscribe  Work with our recruiting firm → https://talent.fitt.co/ Follow us on Instagram → https://www.instagram.com/fittinsider/ Follow us on LinkedIn → linkedin.com/company/fittinsider  Reach out → insider@fitt.co   

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Omar Khalil, Managing Director at Santé Ventures, describes forming and funding startups and  early-stage biotech companies with a focus on clinical data and differentiation as the key value drivers. Omar talks about his interest in 'undruggable targets,' what's happening with the IPO market, an investor shift from biology risk to commercial risk, and building companies through a venture creation process. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

JT's Mix Tape #94 goes straight into one of the strangest technological rabbit holes we've covered yet.Scientists are already combining living human neurons with computer hardware. Biological computers can learn, process information and potentially operate using a fraction of the energy required by traditional computing.So naturally we had to ask the question:Are we accidentally building The Matrix?JT, Brian and Aaron dig into biological computing, AI, advanced robotics, the explosion of data centers, underground infrastructure, virtual worlds, digital consciousness and where all of this could ultimately be heading.We also get into the strange practice of saint relics and veneration, AI companionship, morality in modern entertainment, Hollywood, and—as usual—a few completely unexpected detours.Some of the discussion in this episode is deliberately speculative. We're connecting dots, exploring possibilities and having the conversations you're probably not going to hear anywhere else.Welcome to JT's Mix Tape #94.Become a supporter of this podcast: https://www.spreaker.com/podcast/jt-s-mix-tape--6579902/support.Please support our sponsor Modern Roots Life: https://modernrootslife.com/?bg_ref=rVWsBoOfcFPatreon: https://patreon.com/JT_Follows_JC?utm_medium=unknown&utm_source=join_link&utm_campaign=creatorshare_creator&utm_content=copyLinkJESUS SAID THERE WOULD BE HATERS: https://jtfollowsjc.com/product-category/mens-shirts/JT's Hats: https://jtfollowsjc.com/product-category/hats/Coaching Program: https://www.echoesoftruthnetwork.com/joinTelegram Group: https://t.me/jtsmixtapeNew Trucker Hat: https://www.shopmmca.com/shop/p/jt-follows-jc-hat

In dieser Samstagsfolge von „Alles auf Aktien“ reden wir über den magischen mRNA-Moment. Erleben wir jetzt eine medizinische Revolution oder ist der Hype um Moderna und Biontech übertrieben? Die Antwort liefert unser Gast. Er investiert seit Jahrzehnten in Pharma und Biotech und weiß genau, wer jetzt zum Gewinner wird – wer zum Verlierer. Ihr bekommt von ihm den großen Vergleich der beiden Konkurrenten und vor allem seine Biontech-Analyse räumt mit großen Irrtümern auf. Außerdem nennt unser Profi die spannendsten Übernahme-Kandidaten, seine persönlichen Pharma-Perlen, gibt eine erstaunliche Novo-Nordisk-Prognose ab – und verrät, was er einst von Wassili Papas lernte. Ein Gespräch mit Markus Manns. Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Hier könnt ihr den AAA-Newsletter abonnieren: https://www.welt.de/newsletter/article232797673/Alles-auf-Aktien-Der-taegliche-Boersen-Newsletter-fuer-WELTplus-Abonnenten.html Und – ganz neu: AAA gibt es jetzt auch auf Instagram: https://www.instagram.com/alles_auf_aktien/ Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Anzeige: Eight Sleep: Der Pod 5 reguliert die Temperatur im Bett automatisch, trackt Schlaf- und Gesundheitswerte ohne Wearable und kann so zu besserem Schlaf beitragen. Mit dem Code ALLESAUFAKTIEN erhaltet ihr auf https://www.eightsleep.com/allesaufaktien bis zu 350 Euro Rabatt. Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

This interview is disseminated on behalf of Theralase Technologies Inc.Theralase Technologies (TSXV: TLT | OTCQB: TLTFF) Chairman, President, and CEO Roger White provides an in-depth overview of the company's light-activated small-molecule technology and its development for non-muscle-invasive bladder cancer.Roger discusses the company's completed clinical study enrollment, reported response and safety data, planned regulatory submissions to Health Canada and the FDA, and its collaboration with Ferring Pharmaceuticals.Learn more: https://theralase.com/Watch the full YouTube interview here: https://youtu.be/yeFJUx2w9d8And follow us to stay updated: https://www.youtube.com/@stockstowatchofficial 

In 2006, the Institute of Medicine published From Cancer Patient to Cancer Survivor: Lost in Transition, concluding that millions of Americans were surviving cancer only to find themselves navigating a healthcare system unprepared for life after treatment. The report challenged oncology to recognize that curing cancer was not the end of care, but the beginning of survivorship.This episode explores how the growing cancer survivorship movement exposed the long-term consequences of cancer treatment that medicine had largely overlooked. As survival rates improved following the National Cancer Act of 1971, millions of survivors faced chronic fatigue, neuropathy, infertility, cognitive impairment, financial hardship, employment discrimination, anxiety, depression, and post-traumatic stress. These were not rare complications. They became defining features of survivorship for many patients.Drawing on the work of oncologist Dr. Patricia Ganz, survivor advocate Ellen Stovall, and researchers, clinicians, and survivors across the country, the episode examines how survivorship research expanded beyond recurrence and mortality to include quality of life, psychosocial care, rehabilitation, and long-term follow-up. Their efforts helped establish survivorship care plans, multidisciplinary survivorship clinics, and a broader understanding that cancer affects every aspect of a person's life long after treatment ends.The episode also confronts persistent inequities in survivorship care. Insurance coverage often ends when treatment stops, supportive services remain inconsistent, financial toxicity continues to drive medical hardship, and racial, geographic, and socioeconomic disparities still influence who receives comprehensive follow-up care. For many survivors, finishing treatment simply marks the beginning of another struggle.Modern oncology increasingly recognizes that surviving cancer is measured by more than years of life. It is also measured by quality of life, dignity, access to care, and the ability to rebuild a future after treatment. That evolution remains one of the most significant legacies of the cancer survivorship movement.RELATED LINKSNational Academy of Medicine | ⁠From Cancer Patient to Cancer Survivor: Lost in Transition⁠National Cancer Institute Office of Cancer Survivorship⁠American Society of Clinical Oncology | Survivorship Compendium⁠CancerCare⁠HopeWell Cancer Support⁠National Coalition for Cancer Survivorship⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

How can students start building a future in biotech before they even leave the lab?In this episode, host Elaine Hamm, PhD, sits down with Haley Marcotte, Co-Managing Director of Nucleate New Orleans and a PhD student at Tulane University School of Medicine. Haley shares how discovering biotech as an undergraduate opened her eyes to career possibilities beyond traditional academia and how she is now helping other students make those connections through Nucleate. From workshops on AI and intellectual property to conversations about emerging areas of science, Nucleate brings students, researchers, entrepreneurs, and industry professionals together to learn about life science innovation.In this episode, you'll discover:How Nucleate is helping students explore biotech, entrepreneurship, and career opportunities beyond traditional academic paths.Why connecting students across universities and with the broader life science community can help strengthen emerging biotech ecosystems.How students and industry professionals alike can get involved, build their networks, and help develop the next generation of biotech leaders.Whether you're a student wondering what opportunities exist beyond academia or an established biotech professional looking for a way to give back, tune in to hear how getting involved today can help build a stronger life science community for tomorrow.Links:Connect with Haley Marcotte and learn about Nucleate New Orleans.Connect with Elaine Hamm, PhD, and learn about Tulane Medicine Business Development and the School of Medicine.Check out Nucleate's event on September 10, 2026, at 6pm.Connect with Sammy Vodovoz and Chad Steele, PhD.Learn more about NOBIC, The BioChallenge, and Tulane Innovation Institute.Connect with Ian McLachlan, BIO from the BAYOU producer.Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

In 1967, breast surgeon Dr. Harold P. Freeman arrived at Harlem Hospital expecting to treat cancer. Instead, he confronted a healthcare system where poverty, racism, lack of insurance, and institutional barriers often determined who lived long enough to receive treatment. Patients frequently arrived with advanced disease, not because medicine lacked answers, but because access to care had failed them.This episode explores how cancer survivorship expanded beyond medical breakthroughs to include healthcare access, health equity, and organized advocacy. Building on the early work of the National Coalition for Cancer Survivorship (NCCS), it examines the recognition that surviving cancer depended not only on research, but also on whether patients could navigate a fragmented healthcare system.Freeman responded by creating one of the nation's first patient navigation programs at Harlem Hospital in 1990. Community-based navigators helped patients overcome practical barriers including insurance, transportation, appointments, communication, and fear. The model dramatically improved timely diagnosis and treatment, increased breast cancer survival in Harlem, and ultimately inspired the Patient Navigator Outreach and Chronic Disease Prevention Act of 2005, establishing navigation as a cornerstone of modern oncology care.The episode also follows cancer survivor Ellen Stovall, whose leadership transformed survivorship into a national policy movement. Through the NCCS, she united advocates across cancer types, fought for insurance protections, expanded access to clinical trials, helped shape the creation of the Office of Cancer Survivorship at the National Cancer Institute, and organized the landmark 1998 National March for Cancer Survivorship in Washington, D.C. Her work reframed survivorship as a public policy issue rather than a personal experience.Together, Freeman and Stovall demonstrated that scientific progress alone could not eliminate disparities in cancer outcomes. Their work established two enduring principles that continue to shape oncology today: patients need someone to help them navigate care, and survivors must have a voice in the policies that govern it. Modern cancer survivorship depends on both.RELATED LINKSNational Coalition for Cancer Survivorship⁠Harold P. Freeman Patient Navigation Institute⁠National Cancer Institute Office of Cancer Survivorship⁠Patient Navigator Outreach and Chronic Disease Prevention Act of 2005⁠American Cancer Society⁠Tuskegee Study Timeline | Centers for Disease Control and Prevention⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Brian Sullivan, CEO at Celcuity, talks about winning the company's first FDA approval for Revtorpyk, a kinase inhibitor for breast cancer patients, and why targeting an “untreated disease mechanism” can beat chasing a single mutation. Brian also discusses the process for licensing a shelved Pfizer asset for development, designing Phase 3 trials that challenge assumptions, the benefits of FDA's Real-Time Oncology Review, and managing downside risk while advancing new indications, all while building a launch-ready company without losing pipeline momentum. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Welcome to a very, very, very special bonus episode of Out of Patients, and one unlike anything published on this feed before. For nearly 20 years, Matthew Zachary has handed these microphones to patients, caregivers, doctors, advocates, troublemakers, and people with something worth saying. This time, he handed them to his daughter. Hannah Greenzweig grew up around this show, and now she has commandeered the studio with 3 of her wonderfully creative high school friends to talk about something they built entirely themselves. There is an enormous amount of Dad Pride baked into this episode, along with the strange and wonderful realization that sometimes your kid grows up, takes your chair, takes your microphone, and produces a better show without you.Hannah Greenzweig, Michael Aidinov, Gwendolyn Baldini, and Astronomy are student artists from the Roundabout Youth Ensemble at James Madison High School in Brooklyn. Working alongside teaching artists from Roundabout Theatre Company, they spent a school year creating an original play from the ground up, writing every scene, developing every character, and producing the performance themselves.Instead of discussing a Broadway production, they dissect one they invented.Their play, Subject Matter, began with a room full of improbable ideas. Murderous bounce houses, pirate family sagas, underwater adventures, courtroom dance battles, and birthday parties at math museums all competed before the group settled on an absurd rivalry between New York's fictional History Museum and Math Museum. From there, they built a fully staged comedy about institutional competition, sabotage, oversized personalities, and the unexpected discovery that history and mathematics need each other more than either side wants to admit.The conversation pulls back the curtain on a creative process most audiences never see. The students explain how scenes evolved through constant rewrites, how characters emerged from improvisation, how costumes came together with last minute ingenuity, and how rehearsals often collapsed into uncontrollable laughter. They recount cutting favorite ideas, solving production problems with limited resources, and trusting each other enough to keep rewriting until the story worked.The episode also captures something harder to script: teenagers speaking honestly about collaboration without adults translating their experience. They celebrate classmates who stepped into unexpected roles, teachers who quietly held the production together, and the strange joy of creating something that exists only because everyone showed up.It is a conversation about theater, friendship, education, creativity, and what happens when 4 young artists get the microphones and the adults get out of the way.RELATED LINKSRoundabout Theatre CompanyRoundabout Youth EnsembleJames Madison High SchoolFEEDBACKLike this bonus episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

A man is struck by a car on the streets of Los Angeles. In the emergency department, a CT scan ordered to look for traumatic injuries reveals something nobody expected: a mass in his colon. Days later, sitting across from Dr. Belinda Waltman, he calls the accident “a blessing in disguise.” Then he changes the subject. He is less worried about cancer than about whether he can afford to miss another day of work. In this season finale of Standard Deviation, host Dr. Oliver Bogler explores what happens when biomedical science collides with the realities of the healthcare safety net. Dr. Waltman, a primary care physician in Los Angeles County, specializes in expedited cancer workups for uninsured and underinsured patients. Every diagnosis arrives carrying another set of questions about housing, transportation, food insecurity, wages, and survival that rarely appear in medical records or scientific literature. For years, Waltman carried those stories without knowing how to bring them into the academic record. As a full-time clinician without a research lab, grant funding, or publication pipeline, she faced barriers familiar to many working scientists and physicians whose most important observations happen outside traditional research settings. With support from the Life Science Editors Foundation's JEDI program, those experiences became The Margins Matter, a narrative medicine essay published in JAMA that argues the social realities surrounding cancer care are not background details. They are part of the disease itself. Bogler traces how editorial mentorship transformed lived clinical experience into published scholarship while asking a larger question about who gets to shape the scientific record. The conversation examines cancer care, Medicaid, health-related social needs, medical publishing, and the structural incentives that determine which stories become evidence and which disappear from view.The result is a conversation about documentation, visibility, and why the margins of medicine often determine who survives long enough to benefit from its advances.RELATED LINKSDr. Belinda Waltman⁠The Margins Matter | JAMA⁠The Margins Matter | PubMed⁠Life Science Editors Foundation⁠FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of compelling stories that underscore the dynamic shifts and groundbreaking progress within the industry. Recently, Akeso's ivonescimab received a landmark approval for first-line treatment of non-small cell lung cancer (NSCLC) in China. This marks a significant shift in China's regulatory environment, which is increasingly fostering innovative treatment options. Ivonescimab's approval not only enhances Akeso's standing in oncology but also provides new hope for NSCLC patients, a cancer type notoriously difficult to treat. In the arena of mergers and acquisitions, Alfasigma has strategically expanded its reach by acquiring key assets from Nordic Pharma. This acquisition opens doors to new therapeutic areas like arthritis, women's health, and critical care—an astute move to diversify offerings and enhance global market presence. Such strategic expansions are essential for companies aiming to maintain competitive edge and explore untapped markets. Eli Lilly has taken legal action against six U.S. companies involved in unauthorized sales of its experimental weight-loss drug, retatrutide. This highlights ongoing challenges in intellectual property protection, emphasizing the balance between innovation safeguarding and market expansion. The legal actions are part of broader efforts to preserve public safety and ensure proper distribution channels for groundbreaking therapies. On the quality control front, Fresenius faced a setback with the recall of a batch of Actemra biosimilars due to glass particle contamination concerns. This incident serves as a stark reminder of the critical role rigorous quality assurance plays in pharmaceutical manufacturing, especially as biosimilars gain traction for their cost-effectiveness and accessibility. In an intriguing blend of technology and healthcare, Samsung Electronics has secured FDA clearance for its Galaxy Buds earphones to function as over-the-counter hearing aids. This development illustrates the increasing convergence of consumer electronics with medical devices, offering innovative solutions to enhance accessibility in hearing health. Turning to psychedelic therapies, Definium Therapeutics reported significant success in its Phase 3 trials for an LSD-based formulation targeting generalized anxiety disorder. Building on earlier successes in depression studies, Definium is paving the way for psychedelic compounds in mainstream medicine. The results not only bolster confidence in such therapies but also signal a potential paradigm shift in treating mental health disorders. Moreover, Oracle Health has introduced an upgraded patient portal featuring an AI assistant designed to simplify medical records management and appointment scheduling. This advancement is part of a larger trend towards integrating artificial intelligence into healthcare systems to improve patient engagement and streamline processes, ultimately enhancing healthcare delivery efficiency. BridgeBio's ATTR stabilizer Attruby achieved impressive quarterly sales of $222 million, nearing blockbuster status as it captures significant market share in treating transthyretin amyloidosis (ATTR). This success underscores the growing importance of small molecule therapies in addressing complex cardiovascular conditions and reflects an industry trend towards stabilizer-first markets. InduPro has successfully raised $77 million in Series B funding supported by industry leaders like Sanofi and Lilly. The investment is set to propel their cancer pipeline forward with a focus on induced proximity and bispecific antibody platforms—innovations poised to revolutionize oncology treatment by enhancing drug specificity and efficacy. On the regulatory front, Chiesi UK's delayed-release mercaptamine received NHS endorsement for cystinosis treatment—an advancement that expands therapeutic options for patients requiring cystine-depleting therapy. Such regulatory support is crucial for facilitating access to innovative treatments for rare diseases. Amidst these developments, Gilead Sciences licensed MacroGenics' bispecific antibody program—a strategic move to bolster its oncology portfolio through milestone payments and royalties. This reflects a broader industry pattern where larger pharmaceutical companies seek pipeline diversification through strategic partnerships and acquisitions of innovative technologies. In vaccine development news, StablePharma's SPVX02 tetanus-diphtheria vaccine achieved promising Phase 1 results without refrigeration requirements—an innovation that could significantly enhance global vaccination efforts by overcoming cold chain distribution challenges. Finally, Insilico Medicine stands at the forefront of AI integration into drug discovery processes under CEO Alex Zhavoronkov's leadership. By promoting a 'fail-fast' approach at the Bio International Convention, Insilico aims to accelerate drug development timelines while reducing costs—a strategy indicative of biopharma's evolution towards more data-driven decision-making processes. These stories collectively highlight an era marked by rapid innovation within pharmaceuticals and biotech sectors. As companies navigate these complexities through scientific advancements and strategic maneuvers alike—there lies immense potential not only for enhancing patient care but also driving economic growth across global healthcare landscapes.Support the show

Send us Fan MailStella Fosse was a teenager when she determined to publish her first book by the age of 25. That didn't happen.  She published her first book at 68. And it was very different from her early aspirations.Join host Jane Trombley in conversation with Stella, a former Biotech writer who pivoted to “elderotica” — in both nonfiction and as a thread throughout her novels.  During a 25-year career as a tech writer, Stella focused on writing, submitting applications, and gaining FDA approval for Biotech products. Along the way, she joined a group of women authors reading their erotic essays featuring powerful female central characters. Stella began to dabble in the genre, participating in writing and reading her work, what she called “elderotica.” It was time to pivot.  With little more than an idea for a guide for midlife women exploring erotica, Stella published her first book, Aphrodite's Pen: The Power of Writing Erotica After Midlife. It would come as no surprise that the launch party for Aphrodite's Pen was held at a sex toy shop in Berkeley, CA. The rest, as they say, is publishing history. Stella shows us the power of the pivot and a commitment to advocating for women's creativity, often emerging in midlife and beyond. Come join the conversation.Show Notes:Website:  www.stellafosse.comSubstack: stellafosse.substack.comGrandmother Collective on SubstackCrone HubStella's BooksRock On: Power, Sex and Money after 60Write & Sell a Well-Seasoned Romance:Launch Your Author Adventure in Late-Life RomanceVampires of a Certain Age:Five Hundred Years of LovingBrilliant Charming Bastard:Getting Rich is the Best RevengeThe Erotic Pandemic Ball:  Tales of Love in LockdownAphrodite's Pen: The Power of Writing Erotica After MidlifeMentioned in the episode:Joan PriceRuth SaxtonSibylline PressSupport the show

Send us Fan MailIn this episode of the WTR Small Cap Spotlight, Cannara Biotech COO and Interim CFO Nick Sosiak joins WTR's Linda Bolton Weiser and Tim Gerdeman to discuss the company's expansion following the announcement of a long-term international supply agreement with Curaleaf carrying a potential aggregate value of up to C$21 million. The conversation covers Cannara's differentiated approach within the cannabis industry, the market positioning of its three brands, the scale advantages of its two Quebec mega-facilities, growing room economics, the current state of the Canadian cannabis market, the role of innovation in driving share gains, and the path to reaching maximum annual production capacity of 100,000 kg. 

Could family offices help biotech founders unlock new sources of capital in an increasingly challenging fundraising environment?In this episode, host Elaine Hamm, PhD, sits down with Danielle Patterson, Executive Director of Family Office at ISS Market Intelligence, to explore the growing role of family offices in startup investing. Danielle shares her entrepreneurial journey, explains why founders need to move beyond the traditional “spray and pray” approach to fundraising, and offers strategies for identifying family offices whose interests, values, and investment goals align with their companies.In this episode, you'll discover:Why family offices can offer patient, long-term capital - and why founders need to approach them differently from traditional institutional investors.How visibility, value alignment, and genuine relationship-building can help founders establish trust with potential investors.How better market intelligence can help entrepreneurs identify the right family offices and focus their fundraising efforts on relationships with the greatest potential.For biotech founders looking beyond traditional sources of capital, this conversation offers a new way to think about fundraising.Links:Connect with Danielle Patterson and learn about ISS Market Intelligence.Connect with Elaine Hamm, PhD, and learn about Tulane Medicine Business Development and the School of Medicine.Check out Elaine's book recommendations: The Fine Art of Small Talk, The Speed of Trust, How to Talk to Anyone, and The Vault Guide to Schmoozing.Connect with Ian McLachlan, BIO from the BAYOU producer.Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the dynamic landscape of drug manufacturing, regulatory affairs, and scientific breakthroughs that are shaping the future of patient care and therapeutic innovation. Bristol Myers Squibb has made headlines with its substantial $2.3 billion investment in a new manufacturing campus in Houston. This strategic move aims to significantly bolster their capabilities across various modalities including small molecules, biologics, and antibody-drug conjugates. The establishment of this facility is a testament to the growing demand for advanced manufacturing infrastructure needed to support complex therapeutics production. As BMS strengthens its operational capacity, it positions itself to better meet the increasing global demand for innovative treatments. In parallel developments, Jazz Pharmaceuticals is expanding its rare epilepsy pipeline through a $1.3 billion acquisition of Actio Biosciences. This strategic acquisition aligns with Jazz's focus on rare diseases with significant unmet medical needs. By integrating Actio's novel small molecule approach, Jazz aims to leverage these innovative therapies to improve patient outcomes in the rare epilepsy market, highlighting a critical shift towards targeted treatments. Vaderis Therapeutics has successfully raised $152 million in Series B funding, aimed at advancing its AKT-targeting treatment for hereditary hemorrhagic telangiectasia (HHT). This funding will support clinical development efforts, offering hope for patients with this rare vascular disorder who currently have limited therapeutic options. The advancement of such targeted therapies underscores the growing focus on addressing rare diseases within the biotech sector. Clinical trial advancements remain pivotal, with MoonLake Immunotherapeutics reporting positive Phase 3 data for sonelokimab, an IL-17A/F inhibitor targeting psoriatic arthritis. This nanobody-based antibody offers a novel mechanism of action by modulating autoimmune pathways involved in psoriatic arthritis, demonstrating the potential of biologics in managing complex autoimmune conditions. In a transformative approach to drug discovery, Aureka Biotechnologies has raised $100 million in Series B funding to further its platform-enabled efforts in antibody and protein design using AI and machine learning technologies. This integration represents a significant step forward, enhancing efficiency and precision in identifying viable therapeutic candidates. Despite these advancements, regulatory challenges persist. The FDA recently rejected ITM Isotope Technologies' application for 177Lu-edotreotide due to manufacturing concerns related to gastroenteropancreatic neuroendocrine tumors. Such setbacks underscore the critical importance of robust manufacturing practices and regulatory compliance to ensure patient safety and product efficacy. BridgeBio and Alnylam Pharmaceuticals are engaged in a competitive race targeting first-line ATTR-CM patients with differing therapeutic approaches—“silencer” versus “stabilizer” therapies. This debate highlights the intricacies involved in treating transthyretin amyloidosis (ATTR), a condition affecting the heart and nervous system, pointing towards potential breakthrough treatments that could significantly improve patient outcomes. On the regulatory front, President Donald Trump has signed an executive order aimed at revising pediatric vaccine recommendations, reflecting a shift in public health policy that could affect vaccination rates and parental decision-making regarding childhood immunizations. WuXi AppTec recently secured a temporary victory in its legal battle with the U.S. Department of Defense regarding its classification as a Chinese military company. This case highlights the geopolitical complexities faced by global pharmaceutical companies operating in sensitive markets. Meanwhile, technological innovation continues to shape healthcare delivery, exemplified by Abbott's partnership with Google Health to develop an AI-powered health insights application. This collaboration is part of a growing trend toward integrating digital technologies into healthcare to enhance diagnostics and personalized medicine. Finally, strategic corporate restructuring is evident as Aura Biosciences refocuses its R&D efforts on ocular oncology under new leadership. Such moves reflect broader trends within biotech firms to streamline operations and concentrate resources on high-potential therapeutic areas. Overall, these developments illustrate a vibrant pharmaceutical and biotech landscape characterized by scientific innovation, strategic alliances, regulatory shifts, and technological integration—all aimed at advancing patient care and therapeutic efficacy in an increasingly complex global environment. As companies continue to navigate these challenges and opportunities, they are set to reshape the future of drug development with significant implications for patient outcomes worldwide.Support the show

In 1986, 23 survivors, physicians, nurses, attorneys, and community organizers gathered in Albuquerque, New Mexico, for a weekend that would permanently change the language and politics of cancer. Working late into the night, they debated not only strategy, but identity, ultimately declaring that from the moment of diagnosis, every person with cancer is a survivor.This episode traces the social and political forces that gave birth to the modern cancer survivorship movement. As advances in early detection and treatment allowed more people to live beyond cancer, survivors discovered that finishing treatment did not mean returning to normal life. Many faced employment discrimination, loss of insurance, social stigma, infertility, chronic health complications, and a healthcare system that viewed survival as the end of care rather than the beginning of a new chapter.Against the backdrop of the civil rights, disability rights, and community health movements of the 1960s and 1970s, physicians, activists, and survivors challenged medicine's paternalistic culture and demanded a greater voice in decisions affecting their lives. Central to this story are physician and survivor Dr. Fitzhugh Mullan, whose landmark 1985 essay, Seasons of Survival, redefined survivorship as a lifelong continuum, and community organizer Katherine Logan, whose determination united dozens of grassroots organizations into what became the National Coalition for Cancer Survivorship.The coalition's founding established principles that continue to shape oncology today. Survivors were no longer defined solely by disease or treatment outcomes. Their experiences became evidence. Their voices became essential to clinical research, healthcare policy, and patient advocacy. By redefining survivorship as an ongoing experience rather than a destination, the movement challenged medicine to recognize the lasting physical, emotional, financial, and social consequences of cancer.The ideas forged during that weekend in Albuquerque became the foundation of modern cancer survivorship. Nearly 40 years later, the coalition's defining principle, that survivorship begins at diagnosis, continues to influence cancer care, research, policy, and the way millions of people understand life after cancer.RELATED LINKSNational Coalition for Cancer Survivorship⁠National Cancer Institute Office of Cancer Survivorship⁠The New England Journal of Medicine⁠Americans with Disabilities Act (ADA.gov)⁠Library of Congress | Civil Rights History Project⁠White Coat, Clenched Fist by Fitzhugh Mullan⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Pressure is on FDA, policymakers and academic centers in the U.S. to respond to challenges from China, Australia, and beyond to run first in human trials faster and more efficiently. On the latest BioCentury This Week podcast, BioCentury's analysts discuss how stakeholders in the U.S. are responding to the challenge.The analysts also discuss the next frontiers of federated learning in drug discovery and the latest crop of biotech IPOs on NASDAQ, which raised over $1.2B in strong IPO run last week.View full story: https://www.biocentury.com/article/660433#ClinicalTrials #BiopharmaPolicy #DrugDevelopment #BiotechIPO #FederatedLearning00:00- Introduction01:15 - Academic Centers10:42 - Policy Picture15:48 - Grand Rounds Europe Highlights18:01 - Federated Learning28:15 - NASDAQ IPOsTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Guest Full Name: Dr. David-Alexandre (“DA”) C. Gros, MD CEODA's Bio:Dr. Gros has served as Chief Executive Officer and a member of the Board of Directors of Eledon Pharmaceuticals, Inc. since September 2020. He joined Eledon Pharmaceuticals from Imbria Pharmaceuticals Inc., where he served as Co-Founder, Chief Executive Officer and Chairman of the Board of Directors. Prior to Imbria, Dr. Gros was President and Chief Operating Officer of Neurocrine Biosciences, Inc., Chief Business and Principal Financial Officer of Alnylam Pharmaceuticals, Inc., and Chief Strategy Officer of Sanofi, S.A. Before joining Sanofi, Dr. Gros held leadership positions in healthcare investment banking at Centerview Partners, LLC, and Merrill Lynch, Pierce, Fenner & Smith Inc., and in healthcare consulting at McKinsey & Company. He previously served on the Board of Directors of Eliem Therapeutics, Inc., a biotechnology company which he co-founded, and is currently the Executive Chairman of Saint Jean Groupe, S.A., a leading French manufacturer of pasta products since 1935.Dr. Gros earned his Doctor of Medicine from The Johns Hopkins University School of Medicine, a Master of Business Administration from Harvard Business School, and a Bachelor of Arts from Dartmouth College.Company: Eledon Pharmaceuticals, Inc.Ticker: ELDNWebsite: https://eledon.com/About the Company:Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company's lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, islet cell transplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a landscape marked by remarkable scientific breakthroughs, strategic alliances, and regulatory milestones that are shaping the future of healthcare. Novo Nordisk is making waves with its new partnership with Amazon Web Services, utilizing artificial intelligence to accelerate drug discovery for chronic diseases. By integrating cloud computing and machine learning models, this collaboration highlights the increasing role of digital transformation in drug development. Novo Nordisk's commitment to innovation is further underscored by the launch of a new London Innovation Hub, enhancing research capabilities in the UK and demonstrating how technology can streamline the development of novel therapeutics. In clinical trial news, Silence Therapeutics has achieved a significant milestone with its investigational therapy Divesiran. This small interfering RNA therapeutic met primary endpoints in a Phase 2 trial for polycythemia vera, highlighting the potential of RNA-based therapies in treating complex blood disorders. Meanwhile, AbCellera's monoclonal antibody therapy ABCL635 has shown promising Phase 2 data for alleviating menopause-related hot flashes, surpassing existing treatments and underscoring the potential of targeted biologics in women's health. Regulatory achievements are further advancing personalized medicine. LabCorp received FDA approval for its PGDx elio tissue complete CDx companion diagnostic for BRAF-mutant advanced melanoma. This tool is pivotal for identifying patients who could benefit from targeted therapies, enhancing precision medicine approaches in cancer treatment. Similarly, AstraZeneca's Calquence and Enhertu have received notable endorsements, reinforcing the critical role of regulatory bodies in facilitating access to innovative treatments. The industry's business landscape is vibrant with strategic partnerships and acquisitions aimed at advancing therapeutic pipelines. Sobi's $580 million deal with Innate Pharma to advance lacutamab through Phase III lymphoma trials underscores how combining expertise can accelerate drug development and commercialization efforts. Financially, companies like Denali Therapeutics are surpassing revenue expectations with products like their enzyme replacement therapy Avlayah for Hunter syndrome, while fundraising activities are empowering biopharmaceutical companies to drive forward pain and oncology initiatives. Despite these advances, challenges persist. Sionna Therapeutics' recent clinical setback in cystic fibrosis reinforces Vertex Pharmaceuticals' dominance in CFTR modulator therapies. Additionally, Tenax Therapeutics encountered disappointment with TNX-103 failing to meet primary endpoints in a Phase 3 trial for pulmonary hypertension associated with heart failure. Manufacturing capabilities are also a focal point as Bristol Myers Squibb plans a substantial investment in Houston, reflecting an industry trend towards expanding infrastructure to meet demand and ensure supply chain resilience. However, compliance remains critical, as seen with Scholar Rock's decision to drop Novo Nordisk's Catalent facility following an FDA inspection. In contrast to setbacks, some companies are achieving breakthroughs. Jazz Pharmaceuticals' acquisition of Actio Biosciences aims to enhance their epilepsy treatment portfolio by integrating clinical-stage assets into its pipeline—a strategic move reflecting ongoing consolidation within the industry. The promise of genetic-targeted therapies is vividly illustrated by Biogen's ALS treatment Qalsody, marking a major scientific breakthrough as the first FDA-approved drug targeting a genetic cause of ALS. Patients have reported symptom stabilization and improvement—a significant advancement given ALS's progressive nature. Meanwhile, psychedelics are emerging as transformative agents in psychiatric medicine. As traditional medications often fall short, psychedelics offer hope for innovative mental health therapies supported by growing clinical and policy backing. However, navigating regulatory landscapes remains challenging. The FDA's recent actions illustrate ongoing struggles to balance innovation with oversight amidst leadership transitions. Real-world evidence is increasingly influencing regulatory decisions—reshaping how companies approach market access strategies by integrating patient experiences into evidence-based decision-making. In oncology, Replimune's melanoma drug has finally earned FDA approval after previous setbacks—a testament to persistence and the potential impact of innovative cancer therapies on patient outcomes. These developments underscore a dynamic pharmaceutical and biotech industry where breakthrough technologies like genetic-targeted therapies and psychedelics promise transformative impacts on patient care. Yet, they also highlight the complexities of bringing these innovations to market amidst stringent regulatory standards and competitive pressures. As we continue to track these stories, one thing is clear: the relentless pursuit of novel treatments remains at the forefront of advancing global healthcare.Support the show

Dagens ämnen: 0:00 Intro 3:49 AI-krasch 16:40 Semestertankar 22:30 SpaceX 23:57 AbCellera 29:22 Octave 32:17 Guldet rusar och vad gör man med likvider till övers? 35:35 Lämmeltåget 36:50 Makro 39:03 Biotech 41:18 Småbolag 43:41 Veckans Fill or Kill www.instagram.com/fillorkillpodden Tack RoboMarkets! https://open.spotify.com/show/7nqoFzFNOZHoQDUnrwKf4L @RoboMarketsSE

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Paul Hastings, Founding CEO and Board Member at Nkarta, an allogeneic cell therapy developer, talks about building off-the-shelf CAR NK cell therapies for autoimmune disease. Paul is candid about problems with clinical trial infrastructure in the U.S., what it will take to fix trial access (biotechs should actively facilitate patient access to trials and work with community health centers to establish new trial sites), and why biotech leaders have a responsibility to speak up about federal policies shaping the life sciences innovation ecosystem.    Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

How do you build a thriving biotech ecosystem? In this episode, Caron Trumbo, VP of Operations at VirginiaBio, shares how collaboration, workforce development, commercialization support, and statewide partnerships are helping Virginia become a growing hub for life science innovation. Learn why connecting startups, universities, investors, and healthcare systems is key to turning breakthrough ideas into real-world impact. Caron Trumbo LinkedInVirginiaBio WebsiteVirginiaBio LinkedInDuane Mancini LinkedInProject Medtech WebsiteProject Medtech LinkedInThank you to our sponsors: Ward Law, Wheelhouse DMG, and JumpStart Inc.

Biotech is living through a paradox: the science has rarely looked more powerful, while the institutions behind it have rarely seemed less trusted. The sector that helped accelerate vaccines, advance cancer treatment, and open new frontiers in brain disease is now facing public skepticism, political pressure on science, and rising competition from countries that see biotech as a strategic national asset. That frustration is being sharpened by affordability concerns, with recent polling finding that nearly six in ten U.S. adults worry about paying for prescription drugs. For an industry built around lifesaving innovation, the challenge is no longer just discovering what comes next; it is proving to the public that those breakthroughs are being developed in patients' best interests.So, how can biotech and pharma restore public trust while continuing to deliver the breakthroughs patients are waiting for?On I Don't Care, host Dr. Kevin Stevenson speaks with Dr. Jeremy Levin, Chairperson of Ovid Therapeutics and author of Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust. Their conversation explores why the public has lost trust in pharma, how pharmacy benefit managers and rebate structures complicate drug pricing, why biotech should be treated as a strategic national asset, and what the industry must do to reconnect with patients.Top insights from the talk…Trust is biotech's central challenge. Dr. Levin argues that the industry's biggest mistake has been losing sight of its covenant with patients. While biotech has delivered transformative medicines, he says the public often sees the industry as profiting from illness rather than partnering in care.Drug pricing is more complex than the sticker price. Dr. Levin points to pharmacy benefit managers, insurers, rebates, and opaque intermediary structures as major drivers of patient frustration, arguing that patients often blame drug companies without seeing how money moves through the system.American biotech faces a strategic test. Dr. Levin warns that if the United States does not protect scientific institutions, support the FDA, and recognize biotech as a national priority, innovation and investment may move elsewhere, including China.Dr. Jeremy Levin is a physician-scientist and biotechnology executive with deep experience leading life sciences companies, boards, strategy, alliances, and business development. He is Chairperson of both Ovid Therapeutics and Opthea, and he previously founded and led Ovid as Chairperson and CEO. He is also Chairman Emeritus of the Biotechnology Innovation Organization, where he helped guide industry leadership across biotechnology policy, innovation, and patient-focused drug development. Earlier in his career, he held senior leadership roles at Teva Pharmaceuticals, Bristol Myers Squibb, and Novartis.

Het grootste winstmomentum in jaren, zo wordt het al genoemd. Er komen weer beleggers naar Europa toe. Die zien hier een gemiddelde winststijging van 22 procent, lage brandstofprijzen én immuniteit voor volatiele tech-aandelen en weten niet hoe snel ze in moeten stappen. Maar hoe houdbaar is dat winstmomentum? En ben je te laat als je nu nog mee wilt doen met het feest? Dat hoor je in deze aflevering. Verder hebben we het over een kantelpunt bij Berkshire Hathaway. Het investeringsvehikel van Warren Buffett geeft z'n geld weer uit. Zowel aan eigen aandelen als die van anderen. Eindelijke slinkt de cashberg weer. Betekent het dat jij zelf ook weer aan de bak moet? We vertellen je ook nog over mogelijk een van de laatste keren dat we van Ebusco horen. De elektrische bussenbouwer waarschuwde al dat het na dit jaar einde verhaal zou zijn als er geen nieuwe orders binnenkomen, maar wat als bestaande orders afhaken? We praten je bij over het nieuwste gok-doelwit in Zuid-Korea. En we leren je een nieuwe term: Moneymaxxing. Te gast: Justin Blekemolen, van Lynx Beleggen BNR Beurs is een journalistiek onafhankelijke productie, mede mogelijk gemaakt door Saxo. Over de makers: Jelle Maasbach is presentator van BNR Beurs en freelance financieel journalist. Zijn favoriete aandeel om over te praten is Disney, maar daar lijkt hij de enige in te zijn. Sinds de eerste uitzending van BNR Beurs is 'ie er bij. Maxim van Mil is presentator van BNR Beurs en journalist bij BNR, waar hij zich focust op de financiële markten en ontwikkelingen in de tech-wereld. Je krijgt hem het meest enthousiast als hij kan praten over ASML, of oer-Hollandse bedrijven zoals Ahold of ABN Amro. Jorik Simonides is presentator van BNR Beurs, economieredacteur en verslaggever bij BNR. Hij wordt er vooral blij van als het een keer níet over AI gaat. Je hoort hem ook in de BNR-podcast Moerdijk: dorp van de rekening. Milou Brand is presentator van BNR Beurs, freelance podcastmaker en columnist bij het Financieele Dagblad. Jochem Visser is presentator van BNR Beurs, maakt Beursnerd XL en is redacteur bij de podcast Onder Curatoren. Vraag hem naar obscure zaken op financiële markten en hij vertelt je waarom het eigenlijk nóg leuker is dan je al dacht. Over de podcast: Met BNR Beurs ga je altijd voorbereid de nieuwe beursdag in. We praten je in een kleine 25 minuten bij over alle laatste ontwikkelingen op de handelsvloer. We blijven niet alleen bij de AEX of Wall Street, maar vertellen je ook waar nog meer kansen liggen. En we houden het niet bij de cijfers, maar zoeken ook iedere dag voor je naar duiding van scherpe gasten en experts. Of je nu een ervaren belegger bent of net begint met je eerste stappen op de beurs, de podcast biedt waardevolle inzichten voor je beleggingsstrategie. Door de focus op zowel de korte termijn als de lange termijn, helpt BNR Beurs luisteraars om de ruis van de markt te scheiden van de essentie.See omnystudio.com/listener for privacy information.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today's episode delves into the latest innovations and strategic shifts propelling the industry forward. A notable dialogue emerging in psychiatric drug development comes from TLDR Biotech's engagement with Shlomi Raz and Ken Belotsky, co-founders of Palomar Labs. This conversation heralds a transformative shift in psychiatric treatments, moving beyond traditional psychedelics toward novel approaches deeply rooted in human experience. Initially inspired by the therapeutic potential of psychedelics such as psilocybin, early research, notably from Johns Hopkins, sought to establish these compounds within a biopharmaceutical framework. Despite historical evidence supporting their efficacy, challenges persisted in reclassifying these Schedule I substances as viable therapies. Raz and Belotsky, pioneers in this initial psychedelic wave, now lead efforts at Palomar Labs to develop next-generation therapeutics targeting serotonin receptors without the hallucinogenic effects typical of classical psychedelics. This approach seeks to dismantle longstanding industry biases against specific receptor targets known as "anti-targets." A critical concept in their methodology is "neuroplastogens," as popularized by David Olson at UC Davis. These compounds are believed to induce beneficial neuroplastic changes without causing hallucinations. However, Palomar Labs exercises caution, viewing neuroplasticity not as a definitive biomarker for therapeutic efficacy but rather as one of many aspects to consider. Their unconventional "reverse" drug development model begins with anecdotal human experiences and is validated backward through preclinical animal models before advancing to clinical trials. This method relies on overlooked data sources—such as discarded trial reports and traditional medicine use cases—to uncover therapeutic candidates traditionally ignored due to biases against certain receptor targets. For example, they explore therapies for Parkinson's disease bypassing direct dopamine receptor modulation and treatments for Alzheimer's-related aggression avoiding heavily sedative antipsychotics. Palomar Labs' venture studio model emphasizes disciplined capital allocation and an unbiased approach to research outcomes. By prioritizing drug candidates with strong evidence from human experiences, they aim to swiftly advance promising therapies to proof-of-concept stages, readying them for further development by pharmaceutical partners or venture-backed entities. This paradigm shift from target-centric development to a model grounded in empirical human data represents a significant advancement in psychiatric drug discovery. In other industry news, Replimune has successfully navigated regulatory hurdles to secure FDA approval for its melanoma therapy, Tudriqev, following two prior rejections. This achievement underscores the resilience required in drug development and strategic regulatory engagement. The approval highlights the potential of oncolytic virus therapies—Tudriqev employs an innovative approach by using viruses to selectively infect cancer cells while sparing healthy tissue, simultaneously stimulating an immune response. Meanwhile, Eli Lilly continues its dominance in the obesity treatment market with Zepbound, despite new oral competitors. The enduring preference for injectable solutions highlights established efficacy and safety profiles that continue to resonate with healthcare professionals. In China, TransThera has gained regulatory approval for a bile duct cancer treatment, marking a significant step forward for Chinese innovation in oncology. Such advancements not only diversify treatment options but also elevate China's status as a pivotal contributor to global drug development. Challenges persist across the sector, exemplified by Fresenius Kabi's recall of a mislabeled morphine lot due to overdose risks. This incident underscores the vital importance of stringent quality control measures essential for patient safety. The biopharmaceutical landscape also sees Takeda securing FDA approval for its first-in-class orexin receptor agonist targeting narcolepsy—a testament to innovative approaches addressing unmet needs in sleep disorders. Amidst these developments, BioMarin has opted to terminate its $270 million rare disease asset following unsatisfactory Phase 3 results. Such decisions highlight the inherent risks within drug development pipelines and underscore the necessity for strategic flexibility. Leadership changes are shaping corporate trajectories too; BioNTech's appointment of Guido Oelkers as CEO exemplifies this trend. His experience will likely drive strategic realignments crucial for navigating complex industry challenges. Finally, the industry's focus on digital transformation is evident through Bausch + Lomb's partnership with VerilyMe—a collaboration aimed at enhancing dry eye education via digital and AI technologies. These stories collectively embody the dynamic nature of the pharmaceutical and biotech industries—where regulatory achievements, strategic pivots, and technological advancements are continuously redefining therapeutic landscapes and enhancing patient care worldwide. As we continue navigating this rapidly evolving field, staying informed on these developments is crucial for leveraging opportunities and addressing challenges within this innovative sector.Support the show

Can artificial intelligence help cancer patients understand their diagnosis, find more personalized treatment options, and become better advocates for their own care? In this episode of Rx for Biotech, I met with Steve Brown, Founder and CEO of CureWise, an AI-powered patient advocacy platform designed to help people with cancer better understand their disease, prepare questions for their doctors, and explore precision oncology treatment options. For Steve, this mission is deeply personal. After months of unexplained health problems, Steve was ultimately diagnosed with amyloidosis, a rare plasma cell disorder closely related to multiple myeloma. He began using AI agents to analyze his medical records, laboratory results, biopsies, and emerging medical research. Rather than replacing his physicians, AI helped Steve identify patterns, understand the significance of his individual disease biology, and ask more informed questions of specialists. That experience ultimately helped inspire CureWise. In our conversation, Steve explains why he believes the next generation of AI in healthcare should go far beyond simply asking ChatGPT a medical question. CureWise brings together a patient's longitudinal medical information and uses multiple AI models to examine the case from different perspectives - helping patients better understand their cancer and participate more effectively in shared decision-making. The broader vision is not to replace oncologists, but to give patients a more powerful educational and advocacy tool. We also dig into one of the most important ideas in precision cancer care: cancer isn't defined only by where a tumor starts. Increasingly, genomic and molecular testing can reveal mutations and biomarkers that may influence targeted therapies, clinical trials, and other treatment strategies. In this episode: • Steve's personal journey from unexplained symptoms to a rare cancer diagnosis • How he used AI to analyze his medical records • Why AI should support—not replace—oncologists • How CureWise uses multiple AI models to evaluate complex medical information • Why genomic sequencing and biomarker testing matter in precision oncology • Standard-of-care cancer treatment vs. personalized treatment strategies • How patients can prepare more effectively for oncology appointments • AI and clinical trial matching • Why rare molecular subtypes challenge traditional clinical trial models • How AI could democratize access to expertise associated with major cancer centers • The importance of patient advocacy and shared decision-making • Steve's vision for using patient data and AI to accelerate future cancer research Steve's philosophy is particularly relevant for patients and caregivers: AI doesn't have to make the medical decision to be valuable. It can help patients understand the landscape, identify important questions, and participate more effectively in decisions with their oncology team. CureWise was built around that idea- that helping patients understand their specific cancer, identify questions to discuss with their oncology team, and explore clinical trials and emerging therapies that may be relevant to their care. If you or someone you love is navigating a cancer diagnosis, this conversation offers a provocative look at how artificial intelligence, genomic testing, precision medicine, and better patient education could change the cancer journey. Subscribe to Rx for Biotech for conversations with the scientists, physicians, entrepreneurs, and patients shaping the future of personalized medicine and advanced therapies. This episode is for educational purposes and does not provide medical advice. AI tools should not replace evaluation or treatment decisions by qualified healthcare professionals. #AIHealthcare #Cancer #CancerTreatment #PrecisionOncology #PrecisionMedicine #CancerResearch #GenomicTesting #PatientAdvocacy #ArtificialIntelligence #CancerCare #Biomarkers #ClinicalTrials #CureWise #RxForBiotech

In this episode, host Bidemi Ologunde speaks with Jacqueline De Lora, PhD, the CEO/CTO and cofounder of SURFACtoBioTech, a Max Planck spin-off developing surfactant and droplet-based technologies for more efficient, sustainable and data-rich biotechnology experiments. How can microscopic droplets function as individual test tubes? What separates useful AI-enabled laboratory automation from hype? And what does it take to transform frontier research into technology that scientists can reliably adopt? Jacqueline discusses her transition from biomedical researcher to founder, the often-overlooked role of surfactants, and the scientific and commercial challenges of building practical tools for real laboratory workflows.

In dieser Folge von Biertalk geht es am Tag des Bieres ausnahmsweise nicht nur um Tradition, sondern ganz bewusst um die Zukunft. Zu Gast ist Dr. Mark Schneeberger von Eatbeer Biotech in Stralsund, der gemeinsam mit seinem Team an einer Idee arbeitet, die für die Braubranche enormes Potenzial haben könnte: Aus Biertreber, also dem Reststoff aus dem Brauprozess, soll durch Fermentation mit Pilzmyzel ein neuer, hochwertiger Lebensmittelrohstoff entstehen. Wir sprechen darüber, wie aus einer klassischen Brauerei-Nebenströmung plötzlich ein möglicher Wertstoff wird, warum Brauereien lernen müssen, nicht nur in den Rückspiegel zu schauen, und welche Chancen in Themen wie Kreislaufwirtschaft, Fleischalternativen, Fermentation und sogar KI stecken. Es geht um Visionen, um technische Herausforderungen, um neue Geschäftsmodelle für Brauereien – und um die spannende Frage, ob auf dem Grill der Zukunft vielleicht nicht nur Bratwurst, sondern auch „Bier zum Essen“ liegt. Eine Folge über Innovation, Mut und die Lust, Bier einmal ganz anders zu denken.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're delving into a series of pivotal advancements that underscore the dynamic nature of our industry. Starting with Moderna, which has recently secured FDA approval for its mRNA-based influenza vaccine, MFLUSIVA. This marks a monumental leap in leveraging mRNA technology beyond its initial role in COVID-19 vaccine development. The approval not only highlights the technology's adaptability and efficiency but also hints at a transformative future for seasonal vaccines, potentially allowing for rapid responses to influenza virus mutations. In tandem with this development, Takeda has achieved FDA approval for Orzeyful (Oveporexton), an innovative therapy targeting narcolepsy type 1. This represents a significant breakthrough as it targets the root cause of the disorder through orexin receptor modulation. The implication here is profound—offering new hope for patients who have long been underserved by existing treatments and potentially setting a new standard in managing sleep disorders. On the leadership front, Sarepta Therapeutics welcomes new CEO Michael Severino during a critical growth phase. Known for its focus on rare diseases, Sarepta faces the challenge of maintaining its competitive edge and meeting stakeholder expectations in a rapidly evolving market landscape. Meanwhile, AstraZeneca and CSPC Pharmaceutical are enhancing their manufacturing capabilities through a joint venture aimed at bolstering biologics production in China—a strategic move that positions them well within one of the fastest-growing markets for such treatments. This partnership is expected to accelerate the availability of biologic therapies across Asia. In another significant leadership change, Fujifilm Biotechnologies appoints Maja Pedersen as president, signaling a strategic shift towards strengthening its contract development and manufacturing organization operations. This move is reflective of broader industry trends emphasizing operational efficiency and strategic restructuring amid changing market demands. Elsewhere, Emergent BioSolutions has eliminated its top R&D role as part of sweeping restructuring efforts. This decision underscores ongoing challenges companies face in balancing innovation with operational efficiency amidst market pressures. In legal arenas, Galderma Laboratories emerged victorious over Sanofi regarding claims made about its blockbuster drug Dupixent. This victory highlights the importance of substantiating promotional claims in an increasingly competitive pharmaceutical marketing landscape. Turning to clinical trials, Biovie's recent study on Parkinson's disease has sparked debate due to its emphasis on composite endpoints rather than primary ones. While offering insights into specific patient subgroups, this approach raises questions about trial design and result interpretation—a critical factor for drug development success. Investment activities are also shaping industry trends significantly. Notably, Lifemine Therapeutics has secured substantial funding from high-profile investors like Bill Gates and Jeff Bezos. This investment reflects burgeoning interest in innovative biotech platforms capable of addressing complex diseases through unique mechanisms. Moreover, Icon's collaboration with Anthropics aims to integrate AI into clinical trials—an exciting development poised to streamline these processes significantly. By leveraging artificial intelligence capabilities, this partnership could accelerate drug development timelines and improve trial outcomes. Overall, these developments highlight transformative changes within the pharmaceutical and biotech sectors. Innovative therapeutics, strategic partnerships, leadership transitions, regulatory milestones, and technological advancements collectively drive significant progress in patient care and drug development. As we navigate these changes, it's crucial for industry stakeholders to capitalize on emerging opportunities while addressing associated challenges such as regulatory compliance, market competition, and operational efficiencies. Thank you for tuning into Pharma Daily—stay informed and stay ahead!Support the show

In 1971, President Richard Nixon signed the National Cancer Act, transforming cancer research with an unprecedented federal investment and launching what became known as the War on Cancer. The legislation did not emerge from scientific discovery alone. It was the culmination of decades of relentless advocacy by researchers, philanthropists, journalists, and patients who believed cancer demanded the same national commitment that had put astronauts on the Moon.This episode traces the origins of the cancer survivorship movement by returning to a time when cancer was rarely discussed in public, many physicians withheld diagnoses from their patients, and surgery offered few lasting cures. It follows the pioneering work of pathologist Dr. Sidney Farber, whose early chemotherapy research challenged conventional thinking, and Mary Lasker, whose political strategy, fundraising, and public campaigns helped transform cancer from a private tragedy into a national public health priority. Together, they built the coalition that reshaped federal support for oncology research and forever changed the relationship between science, government, and the American public.The story then turns to journalist and breast cancer survivor Rose Kushner, whose refusal to accept the standard one-step radical mastectomy challenged nearly a century of surgical dogma. Working alongside surgeon Dr. Bernard Fisher, Kushner helped bring evidence-based medicine to breast cancer treatment through randomized clinical trials that demonstrated less invasive surgery could achieve equivalent outcomes. Their efforts changed clinical practice, strengthened informed consent, and helped establish the principle that patients should participate in decisions about their own care.The breakthroughs explored in this episode extended far beyond new treatments. They redefined the role of patients in medicine, accelerated clinical research, and laid the foundation for modern cancer survivorship. The movement that followed would not simply help more people live longer. It would change what surviving cancer meant.RELATED LINKSNational Cancer Institute⁠National Cancer Act of 1971⁠American Cancer Society⁠Dana-Farber Cancer Institute⁠National Library of Medicine⁠The New England Journal of Medicine⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of Lab Rats to Unicorns, John Flavin sits down with Andy Robertson, executive director of BioHive Utah and a longtime leader in medical devices, diagnostics, commercialization, and life sciences ecosystem development. Over nearly three decades, Andy has worked across major healthcare companies, private organizations, and startups, helping bring new technologies to market while keeping patient impact at the center of his work. Andy reflects on the internship that unexpectedly launched his medtech career and the mentors, teams, and experiences that shaped his approach to leadership. He shares lessons from working across companies of different sizes, why the best answers are often found outside the office, and how multidisciplinary collaboration, strong culture, and long-term thinking are essential to building successful healthcare companies. Throughout the conversation, Andy and John explore Utah's evolution from its deep roots in medical devices into a growing ecosystem spanning therapeutics, diagnostics, imaging, digital health, and personalized medicine. Andy discusses how BioHive connects founders, universities, experienced industry leaders, and service providers to support the next generation of companies. He also shares his vision for Utah to earn greater recognition as a national and global destination for life sciences innovation.

In this episode, I sit down with Christine Hummel, a healthcare executive with 25 years across the pharmacy benefit manager side, retail and specialty pharmacy, distribution, and pharma manufacturing, including running US Trade and Channel for a major pharma company. Christine has hired teams, rebuilt teams, and decided who gets advocated for the next role many times over, and in this conversation she breaks down exactly what she looks for, and why so many high performers stay stuck chasing a title instead of doing what actually gets them promoted.In this episode, you'll learn:Why chasing the next title can actually slow you downWhat Christine actually looks for before she puts someone's name up for a promotionThe one question to ask yourself before you consider leaving your company for a titleHow to build a network that gets you noticed without waiting to be chosenWhy AI belongs in your career strategy starting now, not laterConnect with Christine:Connect with Christine on LinkedIn here.Listen to the Root to Rising podcast here.Tune in to my interview on the Root to Rising podcast in the episode, How to Build a Career You Don't Need to Escape From, here.Get the Book: Your Worthy Career: A Science-Backed Method to Build a Meaningful Career in Pharma and Biotech here.Work with Me: Learn more and apply to work with me here.Love the podcast?  Share your feedback by leaving us a review. Thank you!Connect on SocialsLinkedInInstagram

Everyone in biotech agrees AI needs more data. Almost no one is willing to pay for it. If you're trying to build or buy a biotech AI model, you've hit the same wall: predictive performance depends on data your budget doesn't cover, and nobody in the field seems willing to close that gap. John Androsavich runs Ginkgo Datapoints, the bio AI data arm of Ginkgo Bioworks. He trained as an RNA scientist, spent years on the pharma side deciding which technologies were worth buying, and now sells the raw biological data everyone claims to want. Ross and John get into why biotech spends a fraction of what tech spends on data, how automation dropped ADME testing to $199 a compound, and what that unlocks for drug discovery pipelines and data science in biotech more broadly. You'll hear why single-cell foundation models don't scale the way the field expected, and how GPT-5 designed its own lab experiments inside an autonomous facility. This one's for data and analytics leaders in biotech who need a clearer read on where to spend on data generation, and where the field is still guessing. It's less useful if you're after a general AI overview with no biotech specifics. Key Takeaways - One Meta investment in a data-labelling vendor outweighs a full year of AI drug discovery venture funding combined, and dwarfs the entire single-cell data market. Biotech's data spend looks nothing like tech's. - Ginkgo's ADME-1 offering runs at roughly a tenth of standard pricing, which is changing when and how much companies test. Teams are now running full tier-one panels earlier instead of triaging molecules before they've generated the negative data models need. - A recent Microsoft Research paper found single-cell foundation model learning saturates at 200,000 to 2 million cells, out of a possible 20 million. Volume alone isn't the lever people assumed it was. - GPT-5 wrote its own experimental protocols for optimising cell-free protein expression, ran them through Ginkgo's autonomous Nebula lab, and hit the lowest price-per-titer ever recorded in the field. Chapter Markers 00:00 Introducing John Androsavich and Ginkgo Datapoints 01:12 Why Ginkgo launched a bio AI data business 05:03 Which companies benefit most from Datapoints 06:31 The paradox: everyone wants data, no one pays 09:00 How automation drives ADME-1's $199 price point 12:59 Testing the Jevons paradox in biotech data buying 16:05 Do we actually know biotech AI's scaling laws? 20:54 Why foundation model builders resist more data 24:59 What an empirical bake-off for bio AI could look like 29:32 The case against sitting on the sidelines 33:26 Inside the Virtual Cell Pharmacology Initiative 41:57 Where VCP fits among other virtual cell projects 44:50 The Antibody Developability Consortium with Apheris 53:57 Autonomous labs and GPT-5 designing its own experiments 59:38 Advice for mid-stage biotech data strategy 01:01:31 Final thoughts on where bio AI investment is heading Useful Links & Resources - Ginkgo Bioworks: [ginkgobioworks.com](https://www.ginkgobioworks.com) - Related episode: Apheris CEO Robin Rohm on federated co-folding (Data in Biotech) - Related episode: Eliza Appel on Lilly's TuneLab and federated learning (Data in Biotech) - CorrDyn: [corrdyn.com](https://www.corrdyn.com) Connect With the Show - Host LinkedIn (Ross Katz): [linkedin.com/in/b-ross-katz](https://www.linkedin.com/in/b-ross-katz/) - Host X: [x.com/brosskatz](https://x.com/brosskatz) - CorrDyn LinkedIn: [linkedin.com/company/corrdyn](https://www.linkedin.com/company/corrdyn/) Where does your organisation sit on the data investment paralysis John describes? Are you waiting for someone else to prove the scaling laws first, or are you buying the data now? Drop your take in the comments. Visit corrdyn.com to learn how CorrDyn can help your organisation extract value from data. #DataInBiotech #BiotechAI #DrugDiscovery #DataScience #GinkgoBioworks

How can biotech startup founders navigate the intersection of science, technology, and data to build truly durable companies?In this episode, host Elaine Hamm, PhD, talks with Cain McClary, MD, Founder and Managing Partner of KdT Ventures, a seed-stage venture firm investing at the convergence of science and technology. A Tulane alumnus and “supply chain junkie,” Cain shares how curiosity, data-driven insight, and strategic storytelling can set biotech innovators apart.In this episode, you'll learn:·       The biggest mistakes biotech startups make—and how to avoid them.·       Why understanding incentives, storytelling, and systems is key to scaling innovation.·       How AI, data ownership, and new consumer health models are reshaping the future of biotech.Tune in to discover how KdT Ventures is rethinking biotech investment—and what it takes to turn scientific insight into lasting impact.Links:Connect with Cain McClary, MD, and check out KdT Ventures.Connect with Elaine Hamm, PhD, and learn about Tulane Medicine Business Development and the School of Medicine. Learn more about PathAI. Check out our fireside chat with Walter Isaacson. Connect with Ian McLachlan, BIO from the BAYOU producer.Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

Long before cancer survivors organized into a movement, Hollywood had already shaped how Americans understood the disease. Films rarely used the word “cancer,” physicians often withheld diagnoses from patients, and the people who survived were almost nowhere to be found on screen.Recorded before The Cancer Mavericks: A History of Survivorship became a documentary series, this bonus conversation explores where the project first began. Matthew Zachary sits down with his mother, Roz Greenzweig, a retired educator and lifelong film enthusiast whose memories of classic cinema became an unexpected lens for understanding how cancer was portrayed throughout the twentieth century.Together, they revisit landmark films including Dark Victory, Love Story, and other iconic portrayals that reflected an era when cancer was treated as unspeakable, inevitable, and almost always fatal. Their conversation contrasts those carefully constructed Hollywood narratives with the lived reality of a family confronting a brain cancer diagnosis in 1995, revealing how popular culture both reflected and reinforced the fears surrounding the disease.The discussion also foreshadows many of the themes explored throughout the documentary series: the evolution of patient advocacy, the emergence of cancer survivorship, the role of caregivers, and the power of storytelling to influence public understanding. Before policy changed, before advocacy organizations grew into national movements, conversations like these were already challenging long-held assumptions about what cancer looked like and who had the right to tell its story.Consider this the prologue to The Cancer Mavericks. Before the movement found its history, it began with a family trying to make sense of the stories they had inherited.RELATED LINKSAmerican Cancer Society⁠National Cancer Institute⁠American Film Institute⁠ER (NBC)⁠50/50 (Official)⁠Chasing Life (ABC Family Archive)⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Questions? Email podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Scott Wapner and the Investment Committee debate their strategy as some key earnings reports boosts the markets to record highs. Plus, we hit the latest Calls of the Day. And later, Josh Brown spotlights some Biotech names in his "Best Stocks in the Market."  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The Cybercrime Wire, hosted by Scott Schober, provides boardroom and C-suite executives, CIOs, CSOs, CISOs, IT executives and cybersecurity professionals with a breaking news story we're following. If there's a cyberattack, hack, or data breach you should know about, then we're on it. Listen to the podcast daily and hear it every hour on WCYB. The Cybercrime Wire is brought to you Cybercrime Magazine, Page ONE for Cybersecurity at https://cybercrimemagazine.com. • For more breaking news, visit https://cybercrimewire.com

When Andrew Miner's son James was diagnosed with an ultra-rare YWHAG mutation, the path forward was anything but clear. In this compelling episode of Sounds of Science, Andrew shares his family's journey, the inspiration behind founding the YWHAG Foundation, and how advancing research is creating new possibilities and renewed hope for families affected by rare diseases.www.ywhagfoundation.org.https://www.criver.com/eureka/ywhag-ultra-rare-mutation-family-hunts-solutions

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Annette Bakker, Ph.D., CEO at the Children's Tumor Foundation, and Andrew Lo, Ph.D., Finance Professor at MIT's Sloan School of Management and Director of the Laboratory for Financial Engineering, talk about the methods and economics for turning abandoned drug candidates into new therapies for patients. Annette and Andrew share the story of Gomekli, a formerly shelved Pfizer drug candidate spun out into SpringWorks Therapeutics, and approved in 2025 for NF Type 1 tumors (Merck KGaA subsequently acquired SpringWorks for $3.9 billion). They also detail plans for bringing more shelved candidates back into development, using a shared data infrastructure and a matchmaking tool to pair interested drug developers with investors and funding. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

“Lincoln Center is multiple stages. I think probably over three dozen stages across 16 acres. It is a vast canvas in and of itself. And then we have this beautiful plaza that leads to this beautiful campus, and that's the visual I think that most people have when they think of Lincoln Center is this beautiful fountain in the center and these three gorgeous buildings.It's New York's biggest plaza, and it feels very vibrant and beautiful. In the summer, we really take that plaza and we transform it into a dance floor. So this idea of also interrupting what people's notion of Lincoln Center is because it's a space that is very aspirational, which is a great thing.”Shanta Thake is the Chief Artistic Officer at Lincoln Center for the Performing Arts—the nation's largest performing arts complex. Before stepping into this role, she spent nineteen years at The Public Theater, shaping the city's cultural landscape through Joe's Pub and expansive community initiatives. Today, she is tearing down walls—both the literal barriers separating Lincoln Center from its neighbors, and the figurative ones that dictate who belongs in our cultural spaces. She views the arts not as a luxury, but as essential civic infrastructure. We are pleased to have Shanta Thake to discuss her journey, the power of radical curation, and the future of public performance.(0:00) Reimagining Lincoln Center(2:27) Art and the Human Experience(4:40) The Curiosity of Childhood(5:44) Alvin Ailey and the Pivot(8:29) The Invisible Arts(9:06) The Power of Public Theater(17:03) Curation, Programming and the Art of Listening(23:42) San Juan Hill and The Wall(31:23) Art as the Oldest Technology(35:02) globalFEST: Music and Connection(38:20) Finding Universal Belonging(41:20) The Gift of Pause(54:27) A Collective CaretakingEpisode Websitewww.creativeprocess.info/podInstagram:@creativeprocesspodcast

Synopsis: The guest on today's podcast is a representative of Braidwell LP, a registered investment adviser. Braidwell invests on behalf of its clients and either holds, or may in the future hold, positions in the securities discussed. His statements are not intended to provide investment advice, discuss comprehensive investment risks, or constitute an offer to transact in any security. The information presented is for general information purposes only and will not be updated. For years, AI has promised to transform drug discovery—but why hasn't that promise translated into more approved medicines? In this episode of Biotech 2050, host Rahul Chaturvedi sits down with Nick Myerberg, Partner and Head of Artificial Intelligence and Technology at Braidwell, for an in-depth discussion on where AI in biotech has succeeded, where it has fallen short, and why the next generation of AI-native drug discovery may finally deliver breakthrough therapies. Nick traces the evolution of computational biology—from early mathematical models to AlphaFold and today's emerging agentic AI systems—and explains why proprietary data, scientific judgment, and tightly integrated laboratory feedback loops are becoming the real competitive advantage. He shares how Braidwell evaluates AI-first biotech companies, what separates lasting platforms from hype, and why the future belongs to organizations that redesign discovery around AI rather than simply adding AI to existing workflows. The conversation also explores autonomous laboratories, AI-designed medicines, the changing economics of biotech, and the evolving role of scientists in an era where human expertise and machine intelligence increasingly work side by side. Whether you're an investor, biotech founder, researcher, or AI enthusiast, this episode offers a thoughtful roadmap for understanding how artificial intelligence is reshaping the future of drug discovery. Biography: Nick Myerberg, Partner and Head of Artificial Intelligence and Technology, Braidwell Nick Myerberg is a Partner and Head of Artificial Intelligence and Technology at Braidwell, a life sciences investment firm dedicated to building and backing companies that transform human health. Working at the intersection of computation, biology, and capital allocation, Nick engineers systems that shape investment decisions and scientific discovery, and he invests in the scientists and founders forging AI-native approaches to biology. Before joining Braidwell, Nick built machine learning systems at Bridgewater Associates and at S&P Global's Kensho Technologies. He was also a founding volunteer at NeighborShare, a nonprofit that connects families in need with local donors. Nick was selected as a member of the inaugural 2026 cohort of the Aspen Institute's Technology Leaders Initiative, a fellowship within the Aspen Global Leadership Network bringing together senior leaders shaping the future of artificial intelligence and frontier technologies. Nick is broadly interested in how advances in computation reshape the pace and structure of scientific discovery, and in building the discovery infrastructure required to increase the world's scientific bandwidth. Nick earned a B.A. from Wesleyan University and later studied history and philosophy of science at the University of Cambridge.

Rebecca Bloom is a former employee benefits and executive compensation attorney who spent more than 25 years helping women navigate cancer, work, insurance, disability coverage, and financial survival. She is the founder and author of When Women Get Sick, a book built from decades inside the legal, workplace, and patient advocacy systems most people only discover after diagnosis.Bloom started in Big Law at Simpson Thacher handling employee benefits and compensation work she originally chose to pay off student loans. Then her mother was diagnosed with breast cancer. Suddenly the language she used in corporate law offices became the language of survival at home. Explanation of benefits forms. Coverage disputes. Second opinions. Disability protections. Medical leave. Bills no one could explain.That collision changed the direction of her life.In this episode, Bloom explains how serious illness quietly turns patients into unpaid administrators managing paperwork, logistics, financial risk, and emotional labor while trying to survive treatment. She breaks down how employer based health insurance shapes nearly every aspect of cancer care in America and why women often carry the invisible burden of protecting everyone else from discomfort while they themselves fall apart.The conversation digs into workplace power, the illusion of the healthcare “safety net,” caregiver exhaustion, and the class divide hiding underneath patient empowerment culture. Bloom explains why educated, insured women with resources still struggle to navigate healthcare bureaucracy and what happens to patients without those advantages.This episode explores cancer care, health insurance, employee benefits, patient advocacy, workplace protections, caregiving, and the structural incentives that force sick people to become project managers of their own survival.RELATED LINKSRebecca BloomWhen Women Get SickBay Area Cancer ConnectionsSimpson Thacher & BartlettFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Our CIO and Chief U.S. Equity Strategist Mike Wilson explains why market leadership is rotating beyond semiconductors and where investors may find opportunities despite near-term volatility.Read more insights from Morgan Stanley.----- Transcript ----- Welcome to Thoughts on the Market. I'm Mike Wilson, Morgan Stanley's CIO and Chief U.S. Equity Strategist. Today on the podcast, I will explain why the recent volatility in markets makes sense. It's Wednesday, July 22nd at 2 p.m. in New York. So, let's get after it. The broadening trade is back and it's gaining steam. We established this thesis last week. Importantly, there's a key reason this broadening trade is likely to continue. One of the more crowded areas of the market—semiconductors—has lost its momentum. As I've also noted before, this is not a call that the AI cycle is over. However, stocks do trade on the rate of change in growth, and expectations often reach a place where they can no longer surprise on the upside. Earnings revisions tend to get too stretched, and capital starts looking for the next place where fundamentals are improving but positioning is still light. This is no different than what happened to other leadership groups earlier this year in areas like precious metals and energy stocks. Remember, I first made the call for market broadening in our November outlook. My view is that the economy had moved into a new expansion after the rolling recession ended in April 2025. Markets were starting to catch on before the Iran conflict interrupted that trend. Investors piled back into the AI trade—especially semis—as oil prices jumped and Fed expectations shifted more hawkish. Back in June, I noted that those earnings revisions were likely nearing their peak. Hyperscale stocks starting to lag was the first indication. Since semis ultimately depend on hyperscaler spending, that divergence usually doesn't last. It doesn't mean the buildout is ending. However, the spenders may be moving from blind enthusiasm to a more disciplined phase as a means of addressing the market's concerns about falling cash flows. We've seen this pattern before. Since ChatGPT launched, this ebbing and flowing between the hyperscaler and semiconductor stocks has happened three times. This is the fourth such adjustment, during which the hyperscaler stocks are likely to outperform the semis. Since a few weeks back, hyperscalers have outperformed semiconductors by almost 30 percent. Another consequence is that the major averages may trade lower in the near term. When a crowded, large-cap leadership group is unwinding, the index can look choppy even as the market underneath is improving. That's the key distinction. The index may struggle, but the broadening can still work. Over the next month, don't be surprised if the S&P 500 trades as low as 7000 before it makes a move to 8000 by year-end. Use this weakness to add to equity positions. I continue to like Consumer Discretionary Goods, Transports, and Biotech. Discretionary Goods remains one of the cleaner expressions of the broadening thesis. Wallet share is shifting from services back toward goods, goods pricing is improving, and earnings revisions are strengthening. Transports continue to show improving revisions as volumes stabilize and pricing gets better. Biotech is one of the more attractive lower-rate beneficiaries, especially if policy expectations are too hawkish, as I think they are. On that last point, the Fed backdrop matters. The June FOMC meeting told us forward guidance is going to be limited, and the inflation path is going to drive policy. The softer-than-expected inflation data last week should allow the Fed to stay on hold rather than hiking. It may take the bond market a few more data points to fully re-price this view. Bottom line, the broadening is in gear, but it may not feel comfortable because it's happening while the crowded momentum trade unwinds, a process that is likely unfinished. That's usually how rotations in market leadership work. Like spring, it's often: in like a lion and out like a lamb. Thanks for tuning in. I hope you found it informative and useful. Let us know what you think by leaving us a review. And if you find Thoughts on the Market worthwhile, tell a friend or colleague to try it out!

In March, China became the first country to approve an invasive brain-computer interface beyond clinical trials. The implant, called NEO, is now available to some patients with limb paralysis due to a spinal cord injury. Ira talks with Wired staff writer Emily Mullin about the significance of this milestone. Plus, brain implants aren't the only development: China's entire biotech industry has skyrocketed in recent years. A decade ago, about 8% of new drug molecules were discovered in China. Now it's over 40%. And more clinical trials are now being conducted there than in the U.S. or Europe. Ira talks with health policy researcher So-Yeon Kang, who's been following the Chinese pharma industry's meteoric rise. Guests: Emily Mullin is a staff writer at Wired.  Dr. So-Yeon Kang is an Assistant Professor of Health Management and Policy at Georgetown University.  Other episodes you may enjoy: Advances In Brain-Computer Interfaces For People With Paralysis How China Is Driving Down Electricity Costs With Renewables Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Follow our show on Instagram, TikTok, Facebook, and Bluesky @scifri and sign up for our newsletters. Got a science question that's keeping you up at night? Call us: 877-472-4374 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.